# Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

> **NCT06834100** · PHASE3 · RECRUITING · sponsor: **NPO Petrovax** · enrollment: 240 (estimated)

## Conditions studied

- Infections
- Meningococcal

## Interventions

- **DRUG:** polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y

## Key facts

- **NCT ID:** NCT06834100
- **Lead sponsor:** NPO Petrovax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834100, "Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06834100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*